Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with no concurrent financing or share offering planned STOCKHOLM, SWEDEN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results